儿童低恶性度神经胶质瘤市场:KOL的洞察

本报告提供全球儿童低恶性度神经胶质瘤市场相关调查，市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

儿童低恶性度神经胶质瘤的现在及未来的治疗流程

调查目的

后期开发平台

• II型泛Raf激化酵素抑制剂
  • Tovorafenib
• MEK抑制剂
  • Selumetinib
• MEK抑制剂+I型BRAF抑制剂
  • Trametinib+ Dabrafenib
• 其他的作用机制
  • Everolimus
  • Bevacizumab

儿童低恶性度神经胶质瘤的治疗的未来趋势与机会

附录

KOL快报

Targeted therapies to become standard of care in paediatric low-grade glioma. How do KOLs assess the potential of targeted drugs as front-line therapies? Day One's tovorafenib set for front line position in paediatric low-grade glioma. What clinical advantages do KOLs identify for this late-stage pan-RAF inhibitor? Leading KOLs critically assess the prospects of pipeline therapies for treating paediatric low-grade glioma.

Table of Contents

Executive summary (13)

Current and future treatment algorithm for pLGG

Research objectives (2)

Late-stage pipeline drugs (81)

• Type II pan-Raf kinase inhibitor (26)
  • Tovorafenib (Day One Biopharmaceuticals) (26)
• MEK inhibitor (21)
  • Selumetinib (Koselugo; AstraZeneca/Merck & Co) (21)
• MEK inhibitor + type I BRAF inhibitor (16)
  • Trametinib + dabrafenib (Mekinist + Tafinlar; Novartis) (16)
• Other mechanisms of action (18)
  • Everolimus (Afinitor; Novartis) (6)
  • Bevacizumab (Avastin; Roche) (12)

Future trends and opportunities in pLGG treatment (11)

Appendix (5)

• KOL details (5)
  • KOLs from North America (3)
  • KOLs from Europe (1)

KOL Bulletins (2)